Polymorphisms in promiscuous PXR: An explanation for interindividual differences in drug clearance?

Pharmacogenetics

Volumn 11, Issue 7, 2001, Pages 551-552

  Forman, B M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; PACLITAXEL; PHENOBARBITAL; PROTEINASE INHIBITOR; RIFAMPICIN; STEROID RECEPTOR; XENOBIOTIC AGENT;

AMINO ACID SUBSTITUTION; DRUG ACTIVATION; DRUG CLEARANCE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; LIGAND BINDING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

HUMANS; METABOLIC CLEARANCE RATE; POLYMORPHISM, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; XENOBIOTICS;

EID: 0034791488     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200110000-00001     Document Type: Short Survey

References (7)

1. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR
2. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets
3. Allosteric effects of DNA on transcriptional regulators
4. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
5. An array of positioned nucleosomes potentiates thyroid hormone receptor action in vivo
6. Orphan nuclear receptors: The exotics of xenobiotics
7. The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants